Clinical Considerations in Selecting and Using Atypical Antipsychotics

CNS Spectrums

Volumn 10, Issue S10, 2005, Pages 12-19

  Newcomer, John W ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33750569229     PISSN: 10928529     EISSN: 21656509     Source Type: Journal    
DOI: 10.1017/S1092852900025177     Document Type: Article

References (54)

1. Jibson, MD, Tandon, R. New atypical antipsychotic medications. J Psychiatr Res. 1998; 32: 215–228.
2. Harris, EC, Barraclough, B. Excess mortality of mental disorder. Br J Psychiatry. 1998; 173: 11–53.
3. Osby, U, Brandt, L, Correia, N, Ekbom, A, Sparen, P. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry. 2001; 58: 844–850.
4. Osby, U, Correia, N, Brandt, L, Ekbom, A, Sparen, P. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res. 2000; 45: 21–28.
5. Dmss, BG, Bradford, WD, Rosenheck, RA, Radford, MJ, Krumholz, HM. Quality of medical care and excess mortality in older patients with mental disorders. Arch Gen Psychiatry. 2001; 58: 565–572.
6. National Institutes of Health. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report. Bethesda, MD: National Institutes of Health; 1998.
7. Allebeck, P. Schizophrenia: a life-shortening disease. Schizophr Bull. 1989; 15: 81–89.
8. Allison, DB, Heo, M, Flanders, DW, Faith, MS, Carpenter, KM, Williamson, DE. Simulation study of the effects of excluding early deaths on risk factor—mortality analyses in the presence of confounding due to occult disease: the example of body mass index. Ann Epidemiol. 1999a;9: 132–142.
9. Dixon, L, Postrado, L, Delahanty, J, Fischer, PJ, Lehman, A. The association of medical comorbidity in schizophrenia with poor physical and mental health. J New Mem Dis. 1999; 187: 496–502.
10. Herran, A, de Santiago, A, Sandoya, M, Fernandez, MJ, Diez-Manrique, JF, Vazquez-Barquero, JL. Determinants of smoking behaviour in outpatients with schizophrenia. Schizophr Res. 2000; 41: 373–381. N1H publication 98-4083.
11. Davidson, S, Judd, F, Jolley, D, Hocking, B, Thompson, S, Hyland, B. Cardiovascular risk factors for people with mental illness. Aust N Z J Psychiatry. 2001; 35: 196–202.
12. Wilson, PW, D'Agostino, RB, Levy, D, Belanger, AM, Silbershatz, H, Kannel, WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998; 97: 1837–1847.
13. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001; 285: 2486–2497.
14. Kato, MM, Currier, MB, Gomez, CM, Hall, L, Gonzalez-Bianco, M. Prevalence of metabolic syndrome in Hispanic and non-Hispanic patients with schizophrenia. Prim Care Companion J Clin Psychiatry. 2004; 6: 74–77.
15. Ford, ES, Giles, WH, Mokdad, AH. Increasing prevalence of the metabolic syndrome among U.S. Adults. Diabetes Care. 2004; 27: 2444–2449.
16. Resnick, HE, Valsania, P, Halter, JB, Lin, X. Differential effects of BM1 on diabetes risk among black and white Americans. Diabetes Care. 1998; 21: 1828–1835.
17. Banerji, MA, Lebowitz, J, Chaiken, RL, Gordon, D, Krai, JG, Lebovitz, HE. Relationship of visceral adipose tissue and glucose disposal is independent of sex in black NIDDM subjects. Am J Physiol. 1997; 273: E425–E432.
18. DeFronzo, RA. The triumvirate: β-cell, muscle, liver. A collusion responsible for NIDDM [Lilly Lecture 1987]. Diabetes. 1988; 37: 667–686.
19. Olefsky, JM, Farquhar, JW, Reaven, GM. Reappraisal of the role of insulin in hypertriglyceridemia. Am J Med. 1974; 57: 551–560.
20. Nasrallah, HA, Mulvihill, T. Iatrogenic disorders associated with conventional vs. atypical antipsychotics. Ann Clin Psychiatry. 2001; 13: 215–227.
21. Rosack, J. FDA to require diabetes warning on antipsychotics. Psychiatric News. 2003; 38: 1–5. Available at: http://pn.psychiatryonline.org/cgi/content/full/38/20/la. Accessed October 31, 2004.
22. Allison, DB, Mentore, JL, Heo, M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999b; 156: 1686–1696.
23. Ayd, F Jr. Highlights of New Schizophrenia Research, III. Available at: http://www.mhsource.com/schizophrenia/highlights3.html. Accessed November 5, 2004.
24. Kane, JM, Carson, WH, Saha, AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2002; 63: 763–771.
25. Nemeroff, CB. Dosing the antipsychotic medication olanzapine. J Clin Psychiatry. 1997; 58(suppl 10):45–49.
26. Kinon, BJ. The routine use of atypical antipsychotic agents: maintenance treatment. J Ciin Psychiatry. 1998; 59(suppl 19):18–22.
27. Koller, E, Schneider, B, Bennett, K, Dubitsky, G. Clozapine-associated diabetes. Am J Med. 2001; 111: 716–723.
28. Koller, EA, Doraiswamy, PM. Olanzapine-associated diabetes mellitus. Pharmocotherapy. 2002; 22: 841–852.
29. Koller, EA, Cross, JT, Doraiswamy, PM, Schneider, BS. Risperidone-associated diabetes mellitus: a pharmacovigilance study. Pharmacotherapy. 2003; 23: 735–744.
30. Koller, EA, Weber, J, Doraiswamy, PM, Schneider, BS. A survey of reports of quetiapine-associated hyperglycemia and diabetes mellitus. J Clin Psychiatry. 2004; 65: 857–863.
31. Yang, SH, McNeely, MJ. Rhabdomyolysis, pancreatitis, and hyperglycemia with ziprasidone. Am J Psychiatry. 2002; 159: 1435.
32. Wirshing, DA, Boyd, JA, Meng, LR, Ballon, JS, Marder, SR, Wirshing, WC. The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry. 2002; 63: 856–865.
33. Gianfrancesco, F, Durkin, MB, Mahmoud, R, Wang, RH. Use of healthcare services by patients treated with risperidone versus conventional antipsychotic agents. Pharmacoeconomics. 2002; 20: 413–427.
34. Koro, CE, Fedder, DO, L'ltalien, GJ, et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. Br Med J. 2002a;325: 243.
35. Caro, JJ, Ward, A, Levinton, C, Robinson, K. The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis. J Clin Psychiatry. 2002; 63: 1135–1139.
36. Simpson, GM, Glick, ID, Weiden, PJ, Romano, SJ, Siu, CO. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Am J Psychiatry. 2004; 161: 1837–1847.
37. Pigott, TA, Carson, WH, Saha, AR, et al. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry. 2003; 64: 1048–1056.
38. Newcomer, JW, Haupt, DW, Fucetola, R, et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry. 2002; 59: 337–345.
39. Henderson, DC, Cagliero, E, Gray, C, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. Am J Psychiatry. 2000; 157: 975–981.
40. Meyer, JM. Novel antipsychotics and severe hyperlipidemia. J Clin Psychopharmacol. 2001; 21: 369–374.
41. Meyer, JM. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry. 2002; 63: 425–433.
42. Koro, CE, Fedder, DO, L'Italien, GJ, et al. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry. 2002b;59: 1021–1026.
43. FDA Psychopharmacological Drugs Advisory Committee. Briefing document for Zeldox® capsules (Ziprasidone HCl). July 19, 2000. Available at: http://www.fda.gov/ohrms/dockets/ac/00/backgtd/3619bla.pdf. Accessed March 2005.
44. McQuade, RD, Jody, D, Kujawa, MJ, et al. Long-term weight effects of aripiprazole versus olanzapine. Poster presented at: 156th Annual Meeting of the American Psychiatric Association; May 17-22, 2003; San Francisco, CA.
45. L'Italien, GJ. Pharmacoeconomic impact of antipsychotic-induced metabolic events. Prev Med Managed Care. 2003; 3(suppl 2):S38–S42.
46. Henderson, DC, Daley, TB, Kunkel, L, Rodrigues-Scott, M, Koul, P, Hayde, D. Clozapine and hypertension: a chart review of 82 patients. J Clin Psychiatry. 2004; 65: 686–689.
47. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004; 27: 596–601.
48. Aquila, R, Emanuel, M. Interventions for weight gain in adults treated with novel antipsychotics. Prim Care Companion J Clin Psychiatry. 2000; 2: 2O–23.
49. Menza, M, Vreeland, B, Minsky, S, Gara, M, Radler, DR, Sakowitz, M. Managing atypical antipsychotic-associated weight gain: 12-month data on a multimodal weight control program. J Clin Psychiatry. 2004; 65: 471–477.
50. Weiden, PJ, Daniel, DG, Simpson, G, Romano, SJ. Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. J Clin Psychopharmacol. 2003; 23: 595–600.
51. Weiden, PJ, Daniel, DG, Leobel, AD, Warrington, L, Dunn, J, Murray, SR. Course of weight and metabolic benefits one year after switching to ziprasidone. Poster presented at: 157th Annual Meeting of the American Psychiatric Association; May 1-6, 2004; New York, NY.
52. Casey, DE, Carson, WH, Saha, AR, et al. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berl). 2003; 166: 391–399.
53. Ried, LD, Renner, BT, Bengtson, MA, Wilcox, BM, Acholonu, WW Jr. Weight change after an atypical antipsychotic switch. Ann Phormacother. 2003; 37: 1381–1386.
54. Berry, S, Mahmoud, R. Improvement of insulin indices after switch from olanzapine to risperidone. Eur Neuropsychopharmocol. 2002; 12(suppl 3):S316.